Treatment strategies and clinical trial design in ADPKD.
More frequent utilization and continuous improvement of imaging techniques has enhanced appreciation of the high phenotypic variability of autosomal dominant polycystic kidney disease, improved understanding of its natural history, and facilitated the observation of its structural progression. At the same time, identification of the PKD1 and PKD2 genes has provided clues to how the disease develops when they (genetic mechanisms) and their encoded proteins (molecular mechanisms) are disrupted. Interventions designed to rectify downstream effects of these disruptions have been examined in animal models, and some are currently tested in clinical trials. Efforts are underway to determine whether interventions capable to slow down, stop, or reverse structural progression of the disease will also prevent decline of renal function and improve clinically significant outcomes.
Torres
Vicente E
VE
Mayo Clinic College of Medicine, Rochester, MN 55905, USA. torres.vicente@mayo.edu
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015316:Genetic Therapy; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D020123:Sirolimus / Q000627:therapeutic use; D000077602:Tolvaptan
D000806:Angiotensin-Converting Enzyme Inhibitors; D000903:Antibiotics, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D001552:Benzazepines; D000077602:Tolvaptan; D015282:Octreotide; D020123:Sirolimus